| Biomarker ID | 1174 |
| PMID | 23846169 |
| Year | 2013 |
| Biomarker | miR-194 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in patients with Biochemical Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- nuclear lumen; nucleoplasm; Gene expression (Transcription); RNA Polymerase II Transcription; Molecular Function organic cyclic compound binding |
| Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 70 patients with Gleason 7 cancers treated by RP, 31 of whom had undergone disease progression following surgery were chosen for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.65 |
| Accuracy | NA |
| Level Of Significance | p = 0.029 |
| Method Used | qRT–PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | miR-194 |